Claritev Corporation (CTEV)
NYSE:CTEV
Want to see CTEV full AI Analyst Report?
Top Page
Claritev
(NYSE:CTEV)
Select Model
Select Model
Rating:49Neutral
Price Target:
$23.50
▼(-50.13% Downside)
Action:ReiteratedDate:04/21/26
The score is held down primarily by high leverage with negative equity and continued net losses, despite an operating rebound and positive operating cash flow. Earnings-call guidance and improving commercial momentum support a moderate outlook, while technicals show short-term strength but appear overextended and still weak versus longer-term averages. Valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Cash generation
Consistent positive operating cash flow (about $117M in 2025) and a strong Q4 levered free cash flow print indicate the business converts revenue into near-term cash. That durability reduces reliance on external financing, helps fund operations and investments, and supports deleveraging over the coming quarters.
Negative Factors
Very high leverage
Heavy indebtedness and negative equity materially constrain financial flexibility and raise refinancing and solvency risk. Even with improving leverage (7.7x), the absolute debt load limits strategic optionality, increases interest and covenant exposure, and makes sustained investment or M&A more difficult without further deleveraging.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Consistent positive operating cash flow (about $117M in 2025) and a strong Q4 levered free cash flow print indicate the business converts revenue into near-term cash. That durability reduces reliance on external financing, helps fund operations and investments, and supports deleveraging over the coming quarters.
Read all positive factors
Claritev (CTEV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$403.98M
Dividend YieldN/A
Average Volume (3M)118.64K
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue Growth3.74%
EPS Growth83.03%
CountryUS
Employees2,700
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-4.88
Shares Outstanding16,966,920
10 Day Avg. Volume86,806
30 Day Avg. Volume118,640
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-4.04
Price to Sales (P/S)0.73
P/FCF Ratio-57.23
Enterprise Value/Market Cap12.42
Enterprise Value/Revenue5.20
Enterprise Value/Gross Profit18.83
Enterprise Value/Ebitda10.56
Forecast
1Y Price Target
$27.25Price Target Upside-42.17% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-8.3
Revenue Forecast (FY)$990.02M
Claritev Business Overview & Revenue Model
Company Description
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based serv...
How the Company Makes Money
null...
Claritev Earnings Call Summary
Earnings Call Date:Feb 23, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call presented a clear improvement in financial performance and commercial momentum: Q4 revenue and adjusted EBITDA grew, Q4 free cash flow was strong, bookings and ACV metrics improved materially, new product capabilities (Network Builder) and AI strategy were highlighted, and management provided constructive 2026 guidance and deleveraging plans. Headwinds include $18M of non-recurring 2025 revenue that will not repeat, an elevated leverage level (7.7x), full-year free cash flow that was still slightly negative, a meaningful shift of some costs from CapEx to OpEx ($10M–$15M), and substantial planned CapEx ($160M–$170M). On balance, the positives around profitable growth, record bookings, margin durability, and forward guidance modestly outweigh the near-term financial and operational challenges.Positive Updates
Q4 Revenue Growth
Total revenue in Q4 was $246.6M, up 6.2% year-over-year, demonstrating durable top-line momentum entering 2026.
Negative Updates
One-Time Revenue Headwinds
2025 included $18M of non-recurring revenue (including a ~$5M one-time benefit in Q4) that will not repeat in 2026, creating a modeling headwind and reducing comparable growth rates.
Read all updates
Q4-2025 Updates
Positive
Negative
Q4 Revenue Growth
Total revenue in Q4 was $246.6M, up 6.2% year-over-year, demonstrating durable top-line momentum entering 2026.
Read all positive updates
Company Guidance
Claritev guided 2026 revenue of $980 million to $1.0 billion (2%–4% growth vs. 2025; 4%–6% growth excluding $18 million of one-time 2025 revenue), with low-single-digit Q1 growth, modest sequential Q2 growth, and 3%–5% growth in the second half as new ACV ramps; full-year adjusted EBITDA of $605 million to $615 million (61%–62% margins, implying ~3.5%–5% like‑for‑like EBITDA dollar growth after normalizing the one‑time items); they expect $10 million–$15 million of costs to shift from CapEx to OpEx, $20 million–$25 million of go‑to‑market and delivery investment, total capital spending of $160 million–$170 million, and free cash flow of $0 million–$10 million, while forecasting double‑digit operating and unlevered free cash flow growth and adjusted cash conversion normalizing to ~50%–55%—all alongside a plan for strong double‑digit ACV bookings growth that will convert to revenue late 2026 and into 2027.Claritev Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
18
Very Negative
Cash Flow
46
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 965.41M | 930.62M | 961.52M | 1.08B | 1.12B |
| Gross Profit | 266.58M | 691.22M | 726.06M | 875.62M | 942.31M |
| EBITDA | 475.44M | -1.01B | 651.93M | 158.32M | 814.99M |
| Net Income | -284.28M | -1.65B | -91.70M | -572.91M | 102.08M |
Balance Sheet | |||||
| Total Assets | 4.89B | 5.15B | 6.96B | 7.37B | 8.22B |
| Cash, Cash Equivalents and Short-Term Investments | 16.81M | 16.85M | 71.55M | 334.05M | 185.33M |
| Total Debt | 4.63B | 4.54B | 4.57B | 4.78B | 4.93B |
| Total Liabilities | 5.06B | 5.07B | 5.26B | 5.58B | 5.88B |
| Stockholders Equity | -173.90M | 84.02M | 1.71B | 1.79B | 2.34B |
Cash Flow | |||||
| Free Cash Flow | -12.28M | -10.51M | 62.87M | 282.63M | 320.10M |
| Operating Cash Flow | 117.32M | 107.62M | 171.72M | 372.36M | 404.69M |
| Investing Cash Flow | -121.02M | -118.12M | -249.79M | -104.45M | -228.38M |
| Financing Cash Flow | 2.36M | -41.31M | -180.99M | -115.74M | -114.68M |
Claritev Technical Analysis
Neutral
47.12
Price Trends
18.12
Positive
27.13
Negative
41.63
Negative
Market Momentum
0.32
Negative
64.15
Neutral
89.90
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTEV, the sentiment is Neutral. The current price of 47.12 is above the 20-day moving average (MA) of 16.97, above the 50-day MA of 18.12, and above the 200-day MA of 41.63, indicating a neutral trend. The MACD of 0.32 indicates Negative momentum. The RSI at 64.15 is Neutral, neither overbought nor oversold. The STOCH value of 89.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CTEV.
Claritev Risk Analysis
Claritev disclosed 61 risk factors in its most recent earnings report. Claritev reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Claritev Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $754.25M | 15.58 | 23.80% | ― | 82.36% | 15.13% | |
69 Neutral | $624.50M | 37.76 | 5.18% | 0.52% | 4.26% | -7.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $403.98M | -2.47 | 378.01% | ― | 3.74% | 83.03% | |
49 Neutral | $349.43M | -0.85 | -69.22% | ― | -26.56% | -531.94% | |
46 Neutral | $145.67M | -2.20 | -47.69% | ― | -4.24% | 64.50% | |
43 Neutral | $101.55M | -0.47 | -54.67% | ― | 1.48% | -119.42% |
* Healthcare Sector Average
CTEV
Claritev
23.81
1.40
6.25%
HSTM
HealthStream
21.31
-11.68
-35.41%
EVH
Evolent Health
3.13
-6.21
-66.49%
HCAT
Health Catalyst
1.38
-2.68
-66.01%
NUTX
Clinigence Holdings
108.24
-10.81
-9.08%
DH
Definitive Healthcare Corp
1.02
-1.69
-62.36%
Claritev Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Claritev Highlights Strategy and Risks at 2026 Investor Day
Neutral
Mar 16, 2026
On March 16, 2026, Claritev Corporation’s management team hosted its 2026 Investor Day in New York, using a detailed presentation to brief shareholders and analysts on its business and financial framework. The company highlighted its relianc...
Business Operations and StrategyStock BuybackFinancial Disclosures
Claritev Posts Turnaround 2025 Results, Issues 2026 Outlook
Positive
Feb 23, 2026
On February 23, 2026, Claritev Corporation reported fourth-quarter 2025 revenue of $246.6 million and a net loss of $80.6 million, with adjusted EBITDA of $151.3 million and strong improvements in operating cash flow and free cash flow versus the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.